Chicago, May 3 – JPMorgan Chase Financial Co. LLC priced $900,000 of 0% review notes March 21, 2024 linked to the lesser performing of the ARK Innovation ETF and the ARK Genomic Revolution ETF, according to a 424B2 filing with the Securities and Exchange Commission.
The notes will be called at par plus an annualized call premium of 19% if each fund closes at or above its initial level on any semiannual review date.
If the notes are not called, the payout at maturity will be par unless either fund falls by more than 50%, in which case investors will be fully exposed to any losses of the worse performing fund.
The notes are guaranteed by JPMorgan Chase & Co.
J.P. Morgan Securities LLC is the agent.
| Issuer: | JPMorgan Chase Financial Co. LLC
|
| Guarantor: | JPMorgan Chase & Co.
|
| Issue: | Review notes
|
| Underlying funds: | ARK Genomic Revolution ETF, ARK Innovation ETF
|
| Amount: | $900,000
|
| Maturity: | March 21, 2024
|
| Coupon: | 0%
|
| Price: | Par
|
| Call: | At par plus 19% annualized rate if each fund closes at or above its initial level on any semiannual review date
|
| Payout at maturity: | If each fund finishes at or above 50% trigger level, par; otherwise, 1% loss for each 1% decline of worse performing index or fund
|
| Initial levels: | $92.99 for Genomic, $127.46 for Innovation
|
| Trigger levels: | $46.495 for Genomic, $63.73 for Innovation; 50% of initial levels
|
| Pricing date: | March 17
|
| Settlement date: | March 22
|
| Agent: | J.P. Morgan Securities LLC
|
| Fees: | 2.95%
|
| Cusip: | 48132TFX9
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
